Erythropoietin for anaemia in cancer patients.
R. W. Johnson Pharmaceutical Research Institute, Raritan, New Jersey.
R
R
Abels
D000368:Aged; D000740:Anemia / Q000209:etiology / Q000628:therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects; D001803:Blood Transfusion; D001853:Bone Marrow / Q000473:pathology; D002945:Cisplatin / Q000009:adverse effects; D004311:Double-Blind Method; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009369:Neoplasms / Q000150:complications*; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D002945:Cisplatin